jtt 501 has been researched along with pirinixic acid in 2 studies
| Studies (jtt 501) | Trials (jtt 501) | Recent Studies (post-2010) (jtt 501) | Studies (pirinixic acid) | Trials (pirinixic acid) | Recent Studies (post-2010) (pirinixic acid) |
|---|---|---|---|---|---|
| 21 | 0 | 1 | 865 | 2 | 200 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Chung, SS; Hu, W; Ko, BC; Li, Z; Liao, C; Lu, XP; Ning, ZQ; Pan, D; Shan, S; Shi, L; Tong, EH; Wong, VK; Yin, Z; Zhou, J | 1 |
1 review(s) available for jtt 501 and pirinixic acid
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
1 other study(ies) available for jtt 501 and pirinixic acid
| Article | Year |
|---|---|
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Topics: Adipose Tissue; Administration, Oral; Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Hypolipidemic Agents; Ketones; Lipid Metabolism; Mice; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship | 2004 |